For female patients, Model 1 was unadjusted; Model 2 was adjusted for age, smoking history, alcohol use, and T2DM duration based on Model 1; and Model 3 was further adjusted for BMI, fatty liver, hypertension, eGFR, fasting C-peptide, HbA1c, Dyslipidemia, serum uric acid, Antihypertensive agents, use of GLP-1RA, use of DPP-4i, and use of insulin based on Model 2. This evidence concerns the gene INS and fatty liver disease.